Targeting Proteomics to Decipher Biology for the Drug Development Pipeline

Dr. Jeffrey Silva explores the role of mass spectrometry-based proteomics on drug discovery, disease mechanisms, and biomarker identification.

Drug discovery and development is a complex and challenging process that requires the identification and characterization of novel drug targets. Proteomics, the large-scale analysis of proteins, is an increasingly important tool in this effort, providing a powerful means to understand disease mechanisms, discover biomarkers, and profile drug pharmacology. Mass spectrometry, a key technology in proteomics, offers high resolution, reproducible and actionable data on a wide range of protein targets.

In this webinar, Jeffrey Silva, PhD, a Principal Scientist in the Proteomics Group at Cell Signaling Technology provides an overview of how mass spectrometry-based proteomics can be used for drug discovery and development. Jeffrey also presents several case studies highlighting how these techniques can be used to gain a deeper understanding of disease mechanisms and as a powerful tool for drug discovery.

Key Topics Include:
- Understand the role of proteomics and mass spectrometry in drug discovery and development
- How to use these techniques to probe disease drivers and drug pharmacology
- How proteomics can be used to discover protein or post-translational modification (PTM) biomarkers
- How to monitor low abundance proteins or critical PTMs using mass spectrometry

Who Should Attend?
- Searching for diagnostic proteomic biomarkers to monitor drug efficacy or disease progression
- Trying to identify on- & off-target effects of small molecule inhibitors or PROTAC-mediated degradation
- Identifying critical signaling pathways modulated upon compound treatment or onset of disease